Clarity Pharmaceuticals (Clarity Pharmaceuticals) Equity-to-Asset : 0.91 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Clarity Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $35.52 Mil. Clarity Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $38.94 Mil.

The historical rank and industry rank for Clarity Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

CLRPF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.9 Med: 0.92 Max: 0.98
Current: 0.91

During the past 2 years, the highest Equity to Asset Ratio of Clarity Pharmaceuticals was 0.98. The lowest was 0.90. And the median was 0.92.

CLRPF's Equity-to-Asset is ranked better than
88.07% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs CLRPF: 0.91

Clarity Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Clarity Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Equity-to-Asset Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Equity-to-Asset

0.92

0.90

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial			0.98	0.92	0.91	0.90	0.91

Competitive Comparison of Clarity Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Clarity Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Equity-to-Asset falls into.

Clarity Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Clarity Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	46.427	/	51.608
	=

Clarity Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	35.515	/	38.937
	=

Clarity Pharmaceuticals (OTCPK:CLRPF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Clarity Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

CU6:Australia

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.